Skip to content

Arginine and Nitric Oxide (NO) Early Prognostic Markers for Non-union Development

Arginine and Nitric Oxide (NO) Metabolism During Bone Healing and Non-union Development- Early Prognostic Markers

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01070576
Enrollment
100
Registered
2010-02-18
Start date
2010-03-31
Completion date
Unknown
Last updated
2010-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrophic Non Union Development, Fracture Healing, Hypertrophic Non Union Development

Keywords

non union, fracture, healing, arginine, NO

Brief summary

Objective: Primary objective is to study the arginine-NO metabolism during fracture healing and dysfunctional fracture healing. Secondary objective: to investigate if differences or decreased arginine and NO concentrations in bone healing form a prognostic marker for non-union development Hypothesis: Early detection of disturbances in the Arginine and nitric oxide metabolism during fracture healing are a good prognostic marker for non-union development. Study design: Prospective observational study. Study population: All acute fracture patients (age \>18 years), with a fracture of the tibia or femur attending the Department of General Surgery, to investigate the Arginine -NO metabolism during normal fracture healing and possible dysfunctional healing. In total 100 patients will be included during this study. Main study parameters/endpoints: Primary endpoints are arginine and Nitric Oxide levels in the plasma during normal and dysfunctional fracture healing the bone in patients with and without non-union Secondary endpoints are levels of Nitric Oxide citrulline, ornithine and other amino acids in bone and in plasma Other parameters: baseline demography details will be obtained, including possible confounders, such as bodyweight, smoking, alcohol abuse, which may interfere with the outcome of this study. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The extent of the burden and risk associated with participation is expected to be low during this study. In total, 7 blood samples will be taken during this study (45ml, in total). During the primary (and possible secondary) surgical procedure, bone debris will be taken. Bone debris is usually discarded but will be used for analysis in this study. There is no extra surgical procedure necessary to obtain the bone debris.

Interventions

OTHERno intervention

no intervention

Sponsors

Maastricht University Medical Center
Lead SponsorOTHER

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Written informed consent * Age \> 18 years * Patient with a fracture of the femur or tibia for which a surgical procedure providing bone debris is performed as therapy

Exclusion criteria

* Patients with another bone fracture in their recent medical history * Infectious complications, such as infected pseudo-arthrosis * Use of chronic corticosteroids or nitrovasodilating medication * Patients with severe metabolic disturbances (liver, and renal insufficiency, diabetes). * Patients with metastases, haematological malignancies or chemotherapy

Design outcomes

Primary

MeasureTime frame
The arginine, NO, citrulline and ornithine levels in plasma and bone debris during normal and dysfunctional fracture healing in patients with and without a non-union1 year

Countries

Netherlands

Contacts

Primary ContactMartijn Poeze, MD, PhD
m.poeze@ah.unimaas.nl+31433876543
Backup ContactNina Wijnands, MD, PhD-student
n.wijnands@ah.unimaas.nl+31 43 3881497

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026